Alerta

SEMA3G抗原结合蛋白及其用途

Resumen de: CN121779558A

0001 本申请涉及生物医药领域，具体涉及SEMA3G抗原结合蛋白及其用途。本申请提供一种分离的抗原结合蛋白，所述抗原结合蛋白结合SEMA3G蛋白，所述抗原结合蛋白包括重链可变区和轻链可变区；所述重链可变区包括如SEQ ID NO.3、11、19任一项所示的HCDR1，如SEQ ID NO.4、12、20任一项所示的HCDR2，如SEQ ID NO.5、13、21任一项所示的HCDR3；所述轻链可变区包括如SEQ ID NO.6、14、22任一项所示的LCDR1，如SEQ ID NO.7、15、23任一项所示的LCDR2，如SEQ ID NO.8、16、24任一项所示的LCDR3；本申请的抗原结合蛋白能够以高亲和力结合上述靶蛋白并且中和其对T细胞功能的抑制活性，从而达到解除肿瘤细胞免疫逃逸功能的作用，促进免疫细胞在体内外对肿瘤细胞的杀伤，可用于制备调节免疫反应或具有抗肿瘤作用的药物。

检测抗GLUL自身抗体的试剂在诊断神经系统自身免疫性疾病中的应用

Resumen de: CN121784288A

0001 本发明公开了检测抗GLUL自身抗体的试剂在诊断神经系统自身免疫性疾病中的应用，属于蛋白诊断试剂制备技术领域。本发明通过对比具有神经系统自身免疫性疾病症状的患者血清和健康人血清，得到以下结果：相比健康人血清，具有神经系统自身免疫性疾病症状的患者血清中存在抗GLUL自身抗体，通过大量的实验进行验证，明确抗GLUL自身抗体可作为诊断神经系统自身免疫性疾病的标志物，尤其是作为辅助诊断神经系统自身免疫性疾病的抗神经细胞抗体。检测抗GLUL自身抗体能够实现神经系统自身免疫性疾病的诊断，尤其是能实现自身免疫性脑炎的辅助诊断。

抗LRP4抗体及其应用

Resumen de: CN121779562A

本发明公开了一种抗LRP4抗体及其应用。其具有依次如SEQ ID NO：2‑4所示的重链CDR1‑3和依次如SEQ ID NO：6‑8所示的轻链CDR1‑3。本发明中的抗LRP4抗体可以有效用于细胞或者组织样本LRP4抗原检测（如免疫荧光检测）或免疫印迹分析，而且能够作为抗LRP4抗体检测试剂盒的阳性标品，直接使用同一套抗人的荧光二抗，简化了检测试剂盒的成分组成。

一种用于诊断阿尔茨海默症的血液星形胶质细胞衍生外泌体标志物及组合

Resumen de: CN121780683A

0001 本发明提供了一种用于诊断阿尔茨海默症的血液星形胶质细胞衍生外泌体标志物及组合。具体地，本发明提供了在血浆中星形胶质细胞衍生的外泌体内的关键核酸标志物（包括SET、GADME、ADAMTSL3、CP等）。相较于外周血中的经典蛋白标志物，这些核酸标志物在体内更稳定不易被降解。使得仅通过采血检测便能检测AD患者脑内的病理状态变化成为可能。并且与传统的蛋白标志物检测方法相比，本发明中的核酸标志物仅通过RT‑qPCR即可完成检测，检测平台具有普适性操作简单且检测成本低。

线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法

Resumen de: CN121775117A

0001 本发明公开了线粒体Rab32在制备用于治疗慢性睡眠剥夺药物中的应用及其研究方法，属于生物医药技术领域。本发明通过建立慢性睡眠剥夺小鼠模型，研究线粒体Rab32与SD小鼠体内蛋白变化的关系，结果表明，线粒体Rab32通过锚定细胞内Sptan1，参与细胞骨架蛋白功能调控，参与神经元的突触再生，由此可得，Rab32是介导SD小鼠神经元突触再生、调节突触可塑性和认知功能障碍的关键分子，该研究结果可能为今后SD相关认知功能障碍的治疗提供新的靶点。

基于APOE-ε2蛋白的阿尔兹海默症检测产品及其应用

Resumen de: CN121784304A

0001 本发明公开了一种标志物在制备阿尔兹海默症的检测产品中的用途，其中，标志物为APOEε2蛋白；检测产品为试剂盒，用于评估阿尔兹海默症疾病进展或严重程度；检测产品所检测的样品为受试者的外周血样本或脑脊液。本发明还提供了一种相应的检测试剂盒，其包含能够特异性结合APOEε2蛋白的结合分子。此外，本发明提供了一种体外非诊断性检测方法，包括使用所述试剂盒检测样本中APOEε2蛋白的浓度，并可对同一受试者的系列样本进行检测以获得浓度动态变化数据。本发明突破了将APOEε2仅作为静态遗传风险因子的传统认知，首次将其外周体液中的蛋白浓度动态变化确立为与AD疾病活动相关的客观量化指标，为AD的疾病进程研究及长期随访管理提供了重要的工具与数据支持。

分析物を検出するための方法

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF

Resumen de: US20260091079A1

0000 Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE

Resumen de: US20260091025A1

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

ANTIBODY WHICH BINDS TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN

Resumen de: US20260092110A1

0000 The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS

Resumen de: US20260092326A1

Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.

OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT

Resumen de: AU2026201900A1

The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions. ar a r

BRAIN-ON-A-CHIP DESIGNS AND LAYOUTS AND METHODS FOR USING SAME

Resumen de: AU2024356356A1

A BoC includes one or more chambers configured to house a population of neurons to be cultured, and one or more cellular-communication platforms placed between at least one pair of chambers from the one or more chambers. The cellular- communication platforms include one or more features/structures configured, shaped, sized, and arranged to promote axonal growth of the population of neurons in a preferred direction and impede axonal growth in directions opposite to the preferred direction, thereby providing control over at least one of, directionality, transmittance, and/or lateral spread between the populations of neurons being cultured. The cellular-communication platforms generate a neuronal circuit between the population of neurons in each pair of the chambers.

BIOLOGICAL STATUS CLASSIFICATION

Resumen de: US20260092926A1

0000 There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.

DIAGNOSIS AND MONITORING OF NEURODEGENERATIVE DISEASES

Resumen de: US20260094269A1

0000 Disclosed is a method for diagnosing a neurodegenerative disease in a subject. The method comprises obtaining from the subject a sample comprising at least one live blood cell, and optionally isolating at least one live blood cell from the sample. The method further comprises generating one or more multispectral or hyperspectral images of the at least one cell, and analysing spectral characteristics of autofluorescence from the at least one cell. Also disclosed is a system configured to aid in the detection or diagnosis of a neurodegenerative disease. Also disclosed is a method for selecting a subject for treatment for a neurodegenerative disease. Also disclosed is a method for monitoring the response of a subject to a therapeutic treatment for a neurodegenerative disease. Also disclosed is a protocol for monitoring the efficacy of a therapeutic treatment for a neurodegenerative disease.

USE OF DISCOIDIN DOMAIN RECEPTOR 2 IN DIAGNOSIS OF NEURODEGENERATIVE DISEASES, AND RELATED COMPUTER READABLE MEDIUM

Resumen de: US20260092920A1

The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.

NERVE CELL ANALYSIS METHOD, KIT, AND SCREENING METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE

Resumen de: WO2026071242A1

The present invention addresses the problem of providing: a nerve cell analysis method with which the localized amount of TDP-43 in nerve cells can be analyzed without labeling TDP-43 with a fluorescent tag or the like and without carrying out gene transfer; a kit for carrying out the nerve cell analysis method; and a screening method for a prophylactic and/or therapeutic agent for a neurodegenerative disease. The present invention provides a nerve cell analysis method involving: a staining step for immunofluorescent staining of nerve cells using an anti-TDP-43 antibody and an antibody that recognizes a stress granule marker; a cell region identification step for identifying the cytoplasm and nuclei of the nerve cells; and an analysis step for analyzing a TDP-43-derived fluorescence signal and a stress granule marker-derived fluorescence signal in the cytoplasm, and analyzing the localized amount of TDP-43 in the nerve cells on the basis of the presence or absence of colocalization of a granular TDP-43 signal and a granular stress granule marker signal in the cytoplasm.

Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia

Resumen de: US20260092931A1

Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.

METHOD FOR DETECTING TEST SUBSTANCE DERIVED FROM AMYLOID-β PRECURSOR PROTEIN, METHOD FOR REDUCING INFLUENCE OF CHELATING AGENT, BUFFER REAGENT, AND REAGENT KIT

Resumen de: WO2026071006A1

The present invention is such that a test substance derived from an amyloid-β precursor protein in a blood sample, a substance that binds to the test substance, and a buffer solution are brought into contact for 6 minutes or less. The buffer solution contains a buffering agent where the concentration at the time of contact is 25 mM or more, and is such that the pH is 3.5 to 9.0. A signal derived from the binding between the test substance and the substance binding to the test substance is measured.

SYSTEMS AND METHODS FOR BIOMARKER DETECTION

Resumen de: US20260092302A1

0000 Provided herein are systems, compositions, and methods for detecting analytes (e.g., proteins, nucleic acid molecules, biomolecules, peptides, antibodies, biomarkers). In an aspect, a method for analyte detection, comprising: (a) providing: (i) a first probe coupled to a surface of a substrate, and (ii) said analyte; (b) binding said first probe coupled to said surface of said substrate and a second probe to said analyte, to generate a complex; (c) using said first probe and said second probe of said complex to generate a reaction product; and (d) detecting said analyte using said reaction product.

METHOD OF USING A FLAVOUR AND AROMA GENERATION SYSTEM

Resumen de: US20260090759A1

0000 A method of measuring an individual's taste and/or smell perception comprises a system to deliver to a user pluralities of artificial flavour sensations to be compared each comprising a plurality of taste and smell components selected from the group comprising sweetness, sourness, saltiness, bitterness, umami, astringency, capsaicin, oiliness, and aroma components. Each plurality contains at least one base flavour and one flavour to be compared against the base flavour. Delivery for the flavours can be through cups, vials, or other vessels. The system may identify a deviation of individual's flavour perception from that of a normal population's flavour perception distribution.

METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER

Resumen de: US20260092932A1

0000 Disclosures herein are directed to methods and compositions for the detection of a panel of proteins as markers for ASD. Based on the results achieved from the methods disclosed herein, ASD can be diagnosed and suitable treatments for ASD may be designed and administered to the subject.

ANTI-APRIL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF

Resumen de: WO2026067804A1

Provided in the present invention is an anti-APRIL antibody or an antigen-binding fragment thereof. Further provided are a polynucleotide encoding the antibody, a vector and host cell for expressing the antibody, a pharmaceutical composition containing the antibody, a method for treating APRIL-associated diseases using the antibody, and the pharmaceutical use thereof.

DIAGNOSIS, PROGNOSIS AND THERAPY OF NEUROINFLAMMATORY AUTOIMMUNE DISEASES USING CELLULAR AND SOLUBLE BLOOD PARAMETERS

Resumen de: US20260092917A1

The present invention relates to a method for determining distinguishing parameters of a neuro-inflammatory disease, said method comprising (a) obtaining parameters from a group of samples, wherein said group of samples comprises at least (i) a first subgroup of samples, and (ii) a second subgroup of samples, and (b) determining distinguishing parameters of the obtained parameters in step (a) at least between said first subgroup of samples and said second subgroup of samples by conducting analytical determination. Further, the present invention relates to a set of distinguishing parameters as well as distinct uses of such sets. Additionally, the present invention relates to a method for determining a subtype of a neuro-inflammatory autoimmune disease in a subject.

SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS

Nº publicación: KR20260044262A 01/04/2026

Solicitante:

알제온인크

Resumen de: WO2020028348A1

Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid- like aggregates, e.g., Alzheimer's disease.